Secondary Central Nervous System Lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-08-01

AUTHORS

Naoto Tomita, Fumio Kodama, Heiwa Kanamori, Shigeki Motomura, Yoshiaki Ishigatsubo

ABSTRACT

This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin’s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma. More... »

PAGES

128-135

Identifiers

URI

http://scigraph.springernature.com/pub.10.1532/ijh97.06091

DOI

http://dx.doi.org/10.1532/ijh97.06091

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020980818

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16926134


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Murine-Derived", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Central Nervous System Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytarabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rituximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Naoto", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kodama", 
        "givenName": "Fumio", 
        "id": "sg:person.01176656731.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176656731.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanamori", 
        "givenName": "Heiwa", 
        "id": "sg:person.01060176576.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Motomura", 
        "givenName": "Shigeki", 
        "id": "sg:person.0727433761.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727433761.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2402573", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053568598", 
          "https://doi.org/10.1038/sj.leu.2402573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-003-0737-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051485520", 
          "https://doi.org/10.1007/s00280-003-0737-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-08-01", 
    "datePublishedReg": "2006-08-01", 
    "description": "This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin\u2019s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma.", 
    "genre": "article", 
    "id": "sg:pub.10.1532/ijh97.06091", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1076985", 
        "issn": [
          "0925-5710", 
          "1865-3774"
        ], 
        "name": "International Journal of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "84"
      }
    ], 
    "keywords": [
      "secondary central nervous system lymphoma", 
      "central nervous system lymphoma", 
      "nervous system lymphoma", 
      "CNS prophylaxis", 
      "CNS involvement", 
      "systemic lymphoma", 
      "system lymphoma", 
      "risk factors", 
      "age-adjusted International Prognostic Index score", 
      "elevated serum lactate dehydrogenase level", 
      "serum lactate dehydrogenase level", 
      "International Prognostic Index score", 
      "Prognostic Index score", 
      "initiation of treatment", 
      "reports of patients", 
      "lactate dehydrogenase levels", 
      "important risk factor", 
      "flow cytometry assay", 
      "intrathecal administration", 
      "liposomal cytarabine", 
      "CNS recurrence", 
      "aggressive NHL", 
      "extranodal sites", 
      "histologic evidence", 
      "histologic subtype", 
      "cell transplantation", 
      "Hodgkin's lymphoma", 
      "polymerase chain reaction", 
      "dehydrogenase levels", 
      "anatomic sites", 
      "correct diagnosis", 
      "cerebrospinal fluid", 
      "prophylaxis", 
      "lymphoma", 
      "advanced stage", 
      "index score", 
      "conventional treatment", 
      "indicator of risk", 
      "cytometry assays", 
      "clinical use", 
      "chain reaction", 
      "treatment", 
      "involvement", 
      "current knowledge", 
      "rituximab", 
      "patients", 
      "transplantation", 
      "cytarabine", 
      "prognosis", 
      "recurrence", 
      "NHL", 
      "main target", 
      "subtypes", 
      "incidence", 
      "diagnosis", 
      "administration", 
      "prevention", 
      "adults", 
      "factors", 
      "scores", 
      "risk", 
      "testis", 
      "presentation", 
      "aggressiveness", 
      "report", 
      "status", 
      "assays", 
      "recent improvements", 
      "review", 
      "initiation", 
      "evidence", 
      "target", 
      "levels", 
      "sites", 
      "improvement", 
      "fluid", 
      "use", 
      "stage", 
      "indicators", 
      "addition", 
      "strategies", 
      "knowledge", 
      "values", 
      "reaction", 
      "approach"
    ], 
    "name": "Secondary Central Nervous System Lymphoma", 
    "pagination": "128-135", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020980818"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1532/ijh97.06091"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16926134"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1532/ijh97.06091", 
      "https://app.dimensions.ai/details/publication/pub.1020980818"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_412.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1532/ijh97.06091"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1532/ijh97.06091'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      22 PREDICATES      126 URIs      116 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1532/ijh97.06091 schema:about N004b0a428c2e4346a0ce15f220ea8b07
2 N03afc7ec2a4843ff83d63d68e3cd7bd7
3 N4a1df607a4104c79856edcff524e64ab
4 N508cc31986384cc998f4b0372c62f7ca
5 N604605381c0c48779996548bac6cb287
6 N7a089e9d6a7745f6b9eebcd127e009ba
7 Nb6b91978e93e475c892067146bbab2f2
8 Nbac9fbc8a9054582984f8236fc363e07
9 Nbadfa90f03ae45f89c9d4e30db7d654b
10 Ne25db49ed1504055b303aa80a6571ff0
11 Ne57316f2b3334a8581cd09bb371f1a45
12 Ne590d65bf4124821a064514cdf297019
13 Nfc7ded9af35043088d5fed62fbee3ae0
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N1a29dd69908a47d89098ea1e58c04262
17 schema:citation sg:pub.10.1007/s00280-003-0737-2
18 sg:pub.10.1038/sj.leu.2402573
19 schema:datePublished 2006-08-01
20 schema:datePublishedReg 2006-08-01
21 schema:description This review summarizes current knowledge of secondary central nervous system lymphoma (SCNSL) in adults. We define SCNSL as CNS involvement not obvious at the initiation of treatment for systemic lymphoma. Recently, polymerase chain reaction and flow cytometry assays of cerebrospinal fluid have become available for the correct diagnosis of SCNSL. We reviewed reports of patients treated without CNS prophylaxis to evaluate the incidence of SCNSL. Elevated serum lactate dehydrogenase levels, the involvement of more than one extranodal site, an advanced stage, a high age-adjusted International Prognostic Index score at presentation, and special anatomic sites of involvement such as the testis are important risk factors for SCNSL. Histologic evidence of aggressiveness is generally an indicator of risk for SCNSL. In addition to conventional treatment, stem cell transplantation, intrathecal administration of rituximab, and liposomal cytarabine have come into clinical use for the treatment of established SCNSL. Prevention of isolated CNS recurrence is thought to be the main target of CNS prophylaxis. The value of CNS prophylaxis according to histologic subtype, status of systemic lymphoma, and other risk factors is summarized.Although prophylaxis is fundamental for treating highly aggressive non-Hodgkin’s lymphoma (NHL), it is beginning to be appreciated for the treatment of aggressive NHL. CNS involvement is almost always fatal; however, a CNS-active strategy could complement other approaches that have led to recent improvements in the prognosis for lymphoma.
22 schema:genre article
23 schema:inLanguage en
24 schema:isAccessibleForFree false
25 schema:isPartOf Nc11670e0948b4495acddacb6bafd2149
26 Nea21d583a3db477bb7f807ad22a4135b
27 sg:journal.1076985
28 schema:keywords CNS involvement
29 CNS prophylaxis
30 CNS recurrence
31 Hodgkin's lymphoma
32 International Prognostic Index score
33 NHL
34 Prognostic Index score
35 addition
36 administration
37 adults
38 advanced stage
39 age-adjusted International Prognostic Index score
40 aggressive NHL
41 aggressiveness
42 anatomic sites
43 approach
44 assays
45 cell transplantation
46 central nervous system lymphoma
47 cerebrospinal fluid
48 chain reaction
49 clinical use
50 conventional treatment
51 correct diagnosis
52 current knowledge
53 cytarabine
54 cytometry assays
55 dehydrogenase levels
56 diagnosis
57 elevated serum lactate dehydrogenase level
58 evidence
59 extranodal sites
60 factors
61 flow cytometry assay
62 fluid
63 histologic evidence
64 histologic subtype
65 important risk factor
66 improvement
67 incidence
68 index score
69 indicator of risk
70 indicators
71 initiation
72 initiation of treatment
73 intrathecal administration
74 involvement
75 knowledge
76 lactate dehydrogenase levels
77 levels
78 liposomal cytarabine
79 lymphoma
80 main target
81 nervous system lymphoma
82 patients
83 polymerase chain reaction
84 presentation
85 prevention
86 prognosis
87 prophylaxis
88 reaction
89 recent improvements
90 recurrence
91 report
92 reports of patients
93 review
94 risk
95 risk factors
96 rituximab
97 scores
98 secondary central nervous system lymphoma
99 serum lactate dehydrogenase level
100 sites
101 stage
102 status
103 strategies
104 subtypes
105 system lymphoma
106 systemic lymphoma
107 target
108 testis
109 transplantation
110 treatment
111 use
112 values
113 schema:name Secondary Central Nervous System Lymphoma
114 schema:pagination 128-135
115 schema:productId N3bf4636cc059447e94bf94bceaecd864
116 N5b09797b3c744e728437812d2cb4989a
117 Na36dba42672f492b93d3cae203573b5b
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020980818
119 https://doi.org/10.1532/ijh97.06091
120 schema:sdDatePublished 2022-05-20T07:23
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher Nc74e87eaf0234f44bd3fad53c8439e61
123 schema:url https://doi.org/10.1532/ijh97.06091
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N004b0a428c2e4346a0ce15f220ea8b07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Lymphoma
129 rdf:type schema:DefinedTerm
130 N03afc7ec2a4843ff83d63d68e3cd7bd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Rituximab
132 rdf:type schema:DefinedTerm
133 N1167130c68aa417980a3affb3f4f4535 rdf:first sg:person.0727433761.60
134 rdf:rest N1cc0216236334d5f910d26ea3952cc0b
135 N1a29dd69908a47d89098ea1e58c04262 rdf:first sg:person.01155656464.01
136 rdf:rest N3689f7b9d47e4137928600030add838b
137 N1cc0216236334d5f910d26ea3952cc0b rdf:first sg:person.01125133646.44
138 rdf:rest rdf:nil
139 N2d81a525fca442e2bb31932e98673ad3 rdf:first sg:person.01060176576.11
140 rdf:rest N1167130c68aa417980a3affb3f4f4535
141 N3689f7b9d47e4137928600030add838b rdf:first sg:person.01176656731.40
142 rdf:rest N2d81a525fca442e2bb31932e98673ad3
143 N3bf4636cc059447e94bf94bceaecd864 schema:name pubmed_id
144 schema:value 16926134
145 rdf:type schema:PropertyValue
146 N4a1df607a4104c79856edcff524e64ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Antibodies, Monoclonal
148 rdf:type schema:DefinedTerm
149 N508cc31986384cc998f4b0372c62f7ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adult
151 rdf:type schema:DefinedTerm
152 N5b09797b3c744e728437812d2cb4989a schema:name doi
153 schema:value 10.1532/ijh97.06091
154 rdf:type schema:PropertyValue
155 N604605381c0c48779996548bac6cb287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Stem Cell Transplantation
157 rdf:type schema:DefinedTerm
158 N7a089e9d6a7745f6b9eebcd127e009ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cytarabine
160 rdf:type schema:DefinedTerm
161 Na36dba42672f492b93d3cae203573b5b schema:name dimensions_id
162 schema:value pub.1020980818
163 rdf:type schema:PropertyValue
164 Nb6b91978e93e475c892067146bbab2f2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Male
166 rdf:type schema:DefinedTerm
167 Nbac9fbc8a9054582984f8236fc363e07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Recurrence
169 rdf:type schema:DefinedTerm
170 Nbadfa90f03ae45f89c9d4e30db7d654b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 Nc11670e0948b4495acddacb6bafd2149 schema:issueNumber 2
174 rdf:type schema:PublicationIssue
175 Nc74e87eaf0234f44bd3fad53c8439e61 schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Ne25db49ed1504055b303aa80a6571ff0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Antimetabolites, Antineoplastic
179 rdf:type schema:DefinedTerm
180 Ne57316f2b3334a8581cd09bb371f1a45 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Female
182 rdf:type schema:DefinedTerm
183 Ne590d65bf4124821a064514cdf297019 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Central Nervous System Neoplasms
185 rdf:type schema:DefinedTerm
186 Nea21d583a3db477bb7f807ad22a4135b schema:volumeNumber 84
187 rdf:type schema:PublicationVolume
188 Nfc7ded9af35043088d5fed62fbee3ae0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Antibodies, Monoclonal, Murine-Derived
190 rdf:type schema:DefinedTerm
191 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
192 schema:name Medical and Health Sciences
193 rdf:type schema:DefinedTerm
194 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
195 schema:name Oncology and Carcinogenesis
196 rdf:type schema:DefinedTerm
197 sg:journal.1076985 schema:issn 0925-5710
198 1865-3774
199 schema:name International Journal of Hematology
200 schema:publisher Springer Nature
201 rdf:type schema:Periodical
202 sg:person.01060176576.11 schema:affiliation grid-institutes:grid.268441.d
203 schema:familyName Kanamori
204 schema:givenName Heiwa
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060176576.11
206 rdf:type schema:Person
207 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
208 schema:familyName Ishigatsubo
209 schema:givenName Yoshiaki
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
211 rdf:type schema:Person
212 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.413045.7
213 schema:familyName Tomita
214 schema:givenName Naoto
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
216 rdf:type schema:Person
217 sg:person.01176656731.40 schema:affiliation grid-institutes:None
218 schema:familyName Kodama
219 schema:givenName Fumio
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176656731.40
221 rdf:type schema:Person
222 sg:person.0727433761.60 schema:affiliation grid-institutes:None
223 schema:familyName Motomura
224 schema:givenName Shigeki
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727433761.60
226 rdf:type schema:Person
227 sg:pub.10.1007/s00280-003-0737-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051485520
228 https://doi.org/10.1007/s00280-003-0737-2
229 rdf:type schema:CreativeWork
230 sg:pub.10.1038/sj.leu.2402573 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053568598
231 https://doi.org/10.1038/sj.leu.2402573
232 rdf:type schema:CreativeWork
233 grid-institutes:None schema:alternateName Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan
234 schema:name Department of Chemotherapy, Kanagawa Cancer Center, Yokohama City University Graduate School of Medicine, Yokohama, Japan
235 rdf:type schema:Organization
236 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
237 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
238 rdf:type schema:Organization
239 grid-institutes:grid.413045.7 schema:alternateName Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan
240 schema:name Department of Hematology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Japan
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...